Can we improve the efficacy of low-dose aspirin?

Thrombosis and Haemostasis

Volumn 112, Issue 6, 2014, Pages 1077-1078

  Grove, Erik L ^a   Storey, Robert F ^b   Kristensen, Steen D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE A2; THROMBOXANE SYNTHASE; ANTITHROMBOCYTIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; LOW DRUG DOSE; PLATELET REACTIVITY; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; CIRCADIAN RHYTHM; DRUG EFFECTS; FEMALE; MALE; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ASPIRIN; BLOOD PLATELETS; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 84914124870     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-08-0702     Document Type: Article

References (26)

1. Bonten TN, Oostrom M, Snoep J, et al. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity: A randomised crossover trial. Thromb Haemost 2014; 112: 1209-1218.
2. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
3. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis. J Am Coll Cardiol 2014; 64: 319-327.
4. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
5. Cohen MC, Rohtla KM, Lavery CE, et al. Metaanalysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79: 1512-1516.
6. Mogabgab O, Giugliano RP, Sabatine MS, et al. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int 2012; 29: 1390-1396.
7. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-1518.
8. Scheer FA, Michelson AD, Frelinger AL, III, et al. The Human Endogenous Circadian System Causes Greatest Platelet Activation during the Biological Morning Independent of Behaviors. PLoS One 2011; 6: e24549.
9. Dalby MC, Davidson SJ, Burman JF, et al. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets 2000; 11: 320-324.
10. Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2010; 105: 336-344.
11. Christensen KH, Grove EL, Wurtz M, et al. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes. Platelets 2014; Epub ahead of print.
12. Wurtz M, Hvas AM, Jensen LO, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int J Cardiol 2014; 175: 274-279.
13. Moore JG, Goo RH. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiol Int 1987; 4: 111-116.
14. Cea Soriano L, Bueno H, Lanas A, et al. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost 2013; 110: 1298-1304
15. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18: 5344-5361.
16. Martin JF, Kristensen SD, Mathur A, et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012; 9: 658-670.
17. Di MG, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-1085.
18. FitzGerald GA, Brash AR, Oates JA, et al. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 72: 1336-1343.
19. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230.
20. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603.
21. Grove EL, Hvas AM, Mortensen SB, et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9: 185-191.
22. Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
23. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011; 4: 180-187.
24. Lordkipanidze M, Harrison P. Aspirin twice a day keeps new COX-1 at bay. J Thromb Haemost 2012; 10: 1217-1219.
25. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
26. Ridker PM, Manson JE, Buring JE, et al. Circadian Variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82: 897-902.